CASE.EDU:    HOME | DIRECTORIES | SEARCH
case western reserve university

Page Expired

 

The page you are attempting to view may be out-of-date.

The page in question has not been verified by its author in quite some time.

If the information provided on the page is time sensitive, it is possible that it is no longer accurate. To ensure that you receive the most current information, we recommend you contact the page's author. He or she can verify whether the information is correct and/or direct you to a more up-to-date page.

Continue to the requested page.

Stanton L. Gerson, MD

Director, Case Comprehensive Cancer Center

Stanton L. Gerson, MD is the Director of Case Comprehensive Cancer Center. Dr. Gerson graduated in 1973 from Harvard College, magna cum laude, and in 1977 from Harvard Medical School, cum laude. From 1977 to 1983, he performed his internship, residency and fellowship training at the Hospital of the University of Pennsylvania. Dr. Gerson has been with the School of Medicine and University Hospitals of Cleveland since 1983. Since 1995, he also has been chief of the Division of Hematology/Oncology. In 1997, he was named the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology and, in 2003, he became the founding director of the Ohio Wright Center for Stem Cell and Regenerative Medicine.

Dr. Gerson's research interests are in the areas of stem cells and DNA repair. In his stem cell research, he developed mesenchymal stem cells as a therapeutic infusion for blood stem cell transplantation and for the correction of genetic disorders. This therapy is approaching FDA approval. He identified a gene therapy strategy method that creates drug resistant stem cells capable of selectively repopulating the recipient without the need for high dose toxic therapy. This strategy is now used experimentally and clinically throughout the country. In the area of DNA repair, he developed inhibitors of DNA repair to improve the efficacy of anti-cancer agents. Dr. Gerson has developed transgenic mouse models that examine the role of critical genes in the stability of stem cell populations over the lifetime of the animal. These studies may predict stem cell diseases of aging and cancer. His research has generated 12 patents in the area of gene therapy and cancer drug development that have been licensed to 3 companies.

Dr. Gerson has multiple NIH grants and over 194 publications, 247 abstracts, 26 book chapters and 12 patents in stem cells and drug discovery. His honors include invited membership in the American Association of Physicians, and the Malinkrodt Scholar award. Dr Gerson is co-editor of the textbook Cancer Gene Therapy and the new text, Clinical Hematology published in 2005. He serves on the External Advisory Boards for the Georgetown Cancer Center, the Moffitt Cancer Center, Sidney Kimmel Johns Hopkins Cancer Center, Holden Iowa Cancer Center, and the University of Chicago Cancer Center. Dr. Gerson has served as the Chair of the Experimental Therapeutics II and serves on the Program Project Study Section for the National Institutes of Health and on numerous other review bodies for the NIH.